Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Interleukin-12 for AIDS-Related Kaposi’s Sarcoma Running head: IL-12 AND LIPOSOMAL DOXORUBICIN FOR KAPOSI’S SARCOMA
暂无分享,去创建一个
S. Steinberg | S. Pittaluga | R. Yarchoan | R. Little | V. Wang | K. Aleman | Pallavi Kumar | K. Wyvill | J. Pluda | E. Read-Connole | A. Catanzaro
[1] S. Steinberg,et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. , 2006, Blood.
[2] S. Monfardini,et al. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy. , 2005, International journal of oncology.
[3] R. Yarchoan,et al. Therapy Insight: AIDS-related malignancies—the influence of antiviral therapy on pathogenesis and management , 2005, Nature Clinical Practice Oncology.
[4] R. Pfeiffer,et al. Survival After Cancer Diagnosis in Persons With AIDS , 2005, Journal of acquired immune deficiency syndromes.
[5] A. Tulpule,et al. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Diamond,et al. Malignancy‐related causes of death in human immunodeficiency virus‐infected patients in the era of highly active antiretroviral therapy , 2005, Cancer.
[7] A H Gandjbakhche,et al. Quantitative Assessment of Tumor Vasculature and Response to Therapy in Kaposi's Sarcoma Using Functional Noninvasive Imaging , 2004, Technology in cancer research & treatment.
[8] D. Podzamczer,et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma , 2004, AIDS.
[9] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[10] S. Krown. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A. d’Arminio Monforte,et al. AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era--the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Sparreboom,et al. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-γ, tumor necrosis factor-α, IL-6, and IL-8 responses , 2003 .
[13] S. Pittaluga,et al. A pilot study of cidofovir in patients with kaposi sarcoma. , 2003, The Journal of infectious diseases.
[14] A. Sparreboom,et al. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] A. Jemal,et al. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. , 2002, Journal of the National Cancer Institute.
[16] D. Katzenstein,et al. A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection , 2002, AIDS.
[17] S. Chevret,et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. , 2001, The Journal of investigative dermatology.
[18] D. Podzamczer,et al. Response to Liposomal Doxorubicin and Clinical Outcome of HIV-1–Infected Patients with Kaposi’s Sarcoma Receiving Highly Active Antiretroviral Therapy , 2001, HIV clinical trials.
[19] S. Steinberg,et al. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine. , 2001, The Journal of infectious diseases.
[20] J. Kaldor,et al. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy , 2001, AIDS.
[21] J. Gutkind,et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. , 2000, Cancer research.
[22] P. Aegerter,et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients , 2000 .
[23] E. Tartour,et al. Cytokines and soluble cytokine receptor induction after IL‐12 administration in cancer patients , 2000, Clinical and experimental immunology.
[24] J. Gutkind,et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. , 2000, Cancer research.
[25] Charles D. McDermott,et al. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] O. Arrieta,et al. Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine. , 1998, European journal of cancer.
[27] E. Geras-Raaka,et al. Human Interferon-γ–inducible Protein 10 (IP-10) Inhibits Constitutive Signaling of Kaposi's Sarcoma–associated Herpesvirus G Protein–coupled Receptor , 1998, The Journal of experimental medicine.
[28] E. Cesarman,et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator , 1998, Nature.
[29] R. Herbst,et al. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models , 1998, Cancer Chemotherapy and Pharmacology.
[30] M. Testa,et al. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S. Nakamura,et al. Vascular endothelial growth factor is a potent angiogenic factor in AIDS-associated Kaposi's sarcoma-derived spindle cells. , 1997, Journal of immunology.
[32] J. Teruya-Feldstein,et al. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo , 1997 .
[33] J. Teruya-Feldstein,et al. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. , 1997, Blood.
[34] E. Cesarman,et al. Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma , 1996, Journal of virology.
[35] D. Herndon,et al. Interleukin‐12 protects thermally injured mice from herpes simplex virus type 1 infection , 1996, Journal of leukocyte biology.
[36] A. Angiolillo,et al. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. , 1996, Blood.
[37] B. Teicher,et al. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma , 1996, Cancer Chemotherapy and Pharmacology.
[38] E. Cesarman,et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. , 1994, Science.
[39] G. Trinchieri,et al. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. , 1994, Blood.
[40] R. Schreiber,et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. , 1994, Journal of immunology.
[41] F. Goebel,et al. Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma. , 1994, Journal of acquired immune deficiency syndromes.
[42] L. Luistro,et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.
[43] J. V. Von Roenn,et al. Epidemiologic analysis of Kaposi's sarcoma as an early and later AIDS outcome in homosexual men. , 1993, American journal of epidemiology.
[44] B. Gazzard,et al. Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study. , 1993, Clinical oncology (Royal College of Radiologists (Great Britain)).
[45] J. Ritz,et al. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. , 1993, Blood.
[46] S. Kaufmann,et al. The role of T-cell subsets and cytokines in the regulation of infection. , 1991, Immunology today.
[47] G. Trinchieri,et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes , 1989, Journal of Experimental Medicine.
[48] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[49] S. Krown,et al. Kaposi's Sarcoma in the Acquired Immune Deficiency Syndrome: A Proposal for Uniform Evaluation, Response, and Staging Criteria , 1989 .
[50] T. Waldmann,et al. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. , 1985, The New England journal of medicine.